November 9, 2022 – Baxter International recently presented new data about the role innovation plays in increasing access to and quality of home dialysis and expanded hemodialysis care at Kidney Week 2022.
“With a growing global deficit between the number of patients with kidney disease and those receiving care, we believe a combination of collaboration, education and innovation is necessary to help increase both access to and quality of care,” said Peter Rutherford, MB BS, PhD., vice president, Medical Affairs, Baxter Renal Care. “Scientific exchange is an important part of the collaboration and education initiatives, which we are very pleased to support at this year’s Kidney Week.”
Here are some of the key highlights:
- Sharesource Remote Patient Management – Baxter’s Sharesource RPM digital health platform allows healthcare professionals to monitor their patients’ home dialysis treatments, and then remotely adjust therapy without the need for patients to make unplanned visits to the clinic. Sharesource is currently serving more than 50,000 patients, across more than 70 countries on Baxter’s APD cyclers. The RPM study presented at Kidney Week 2022 was a cluster randomized, controlled trial, at 21 hospitals across Mexico, where care units were randomly assigned to treat their APD patients with or without RPM.
- HDx Enabled by Theranova – HDx enabled by Theranova removes a wider range of molecules from the blood than traditional HD filters, like high-flux membranes, by targeting the effective removal of large middle molecules (up to 45,000 Da), while selectively retaining essential proteins and maintaining stable albumin levels. These middle molecules have been linked to the development of inflammation, cardiovascular disease, and other co-morbidities in dialysis patients.
The new Theranova data [Abstract #SA-PO405] comes from a simulated study that evaluated the challenges associated with increased removal of larger middle molecules while avoiding clinically relevant albumin loss during a dialysis session. During the study, four commercial dialyzers with comparable surface areas were carefully evaluated for solute clearance and albumin loss during four-hour simulated hemodialysis treatments under standardized conditions.